Entering text into the input field will update the search result below

FDA OK's Lynparza as maintenance treatment of BRCA-mutated pancreatic cancer

  • AstraZeneca (NASDAQ:AZN) and collaboration partner Merck (NYSE:MRK) announce that the FDA has approved LYNPARZA for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
  • The approval follows the recommendation by the FDA Oncologic Drugs Advisory Committee on Dec. 17 for LYNPARZA in this indication.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
MRK
--
AZN
--